Novel KEAP1/NRF2 Target Gene Regulating Ferroptosis and Radioresistance in Lung Cancers | Oncotarget

STK11/ KEAP1 co-mutant lung adenocarcinoma is dependent on SCD1 to evade ferroptosisПодробнее

The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer | RTCL.TVПодробнее

Loss of function mutations in KEAP1 drive lung cancer progressionПодробнее

HyperPETE: A novel Primer extension target enrichment solutionПодробнее

The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer | RTCL.TVПодробнее

BUB1b Impairs Chemotherapy Sensitivity via Resistance to Ferroptosis in Lung AdenocarcinomaПодробнее

The E3 ligase TRIM15 promotes NSCLC progression via the Keap1–Nrf2 signaling pathwayПодробнее

Platinum-Based Doublets As the Cornerstone of First Line TreatmentПодробнее

Pathology Presents: Dr. Gina DeNicolaПодробнее

Abstract 1220: Association Between KRAS/STK11/KEAP1 Mutations & Outcomes in POSEIDON: Durva ± Tr...Подробнее

Case Based Panel Discussion - EGFR - Chemotherapy and EGFR Inhibitor Concurrently or Sequentially?Подробнее

Analysis Identifies NFE2L2 Pathway as a Novel Therapeutic OpportunityПодробнее

Dr. Creelan Discusses Results of Anti-PD-L1 Antibody in Combination with Gefitinib in NSCLCПодробнее

Webinar: First-in Human-Studies of FGFR Inhibitor KIN-3248 and RAF Inhibitor KIN-2787Подробнее

Novel Non-Immunotherapy Targets and Agents in Gastroesophageal CancerПодробнее

The Mechanisms of Nrf2 activation diagrammatically explainedПодробнее

Dr. Burtness on Immunotherapy and Radioresistance in Head and Neck CancerПодробнее

Integrated genomic correlates of response to PD-1 inhibitor nivolumab in mRCCПодробнее